Suscribirse

SARS-CoV-2 antibody testing—questions to be asked - 22/07/20

Doi : 10.1016/j.jaci.2020.05.020 
Mustafa K. Özçürümez, MD a, , Andreas Ambrosch, MD b, , Oliver Frey, MD c, d, , Verena Haselmann, MD e, , Stefan Holdenrieder, MD f, , Michael Kiehntopf, MD g, , Michael Neumaier, MD e, , Michael Walter, MD h, i, , Folker Wenzel, MD j, , Roman Wölfel, MD k, l, , Harald Renz, MD m,
on behalf of the

COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL)

a Department of Laboratory Medicine of the Medical Clinic at the University Medical Center Knappschaftskrankenhaus Bochum, Ruhr University, Bochum, Germany 
b Institute of Laboratory Medicine, Microbiology and Hygiene, Barmherzige Brüder Hospital, Regensburg, Germany 
c Institute of Laboratory Medicine, Brandenburg Medical School, Brandenburg an der Havel, Germany 
d Institute of Medical Diagnostics, Berlin, Germany 
e Institute of Clinical Chemistry, University Medicine Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany 
f Institute for Laboratory Medicine, German Heart Centre, Technical University Munich, Munich, Germany 
g Department of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, Jena, Germany 
h Institute of Clinical Chemistry and Laboratory Medicine, Rostock University Medical Center, Rostock, Germany 
i Institute of Laboratory Medicine, Clinical Chemistry, and Pathobiochemistry, Charité University Medical Center, Berlin, Germany 
j Faculty of Medical and Life Sciences, Hochschule Furtwangen, Furtwangen, Germany 
k Bundeswehr Institute of Microbiology, Munich, Germany 
l German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany 
m Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps Universität Marburg, German Center for Lung Research (DZL), Marburg, Germany 

Corresponding author: Mustafa K. Özçürümez, MD, Department of Laboratory Medicine of the Medical Clinic at the University Medical Center, Knappschaftskrankenhaus Bochum, Ruhr University, In der Schornau 23-25, 44892 Bochum, Germany.Department of Laboratory Medicine of the Medical Clinic at the University Medical CenterKnappschaftskrankenhaus BochumRuhr UniversityIn der Schornau 23-25Bochum44892Germany

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field.

El texto completo de este artículo está disponible en PDF.

Key words : Antibody response, COVID-19, diagnostic pathway, external quality assurance, immunity, immunoassay, neutralization assay, respiratory tract infections, serologic tests, severe acute respiratory syndrome coronavirus 2

Abbreviations used : COVID-19, EQA, NPV, PPV, SARS, SARS-CoV-2


Esquema


 H.R. is funded by the Universities Giessen Marburg Lung Center (UGMLC) and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 146 - N° 1

P. 35-43 - juillet 2020 Regresar al número
Artículo precedente Artículo precedente
  • Clinical testing for COVID-19
  • Stephanie Ward, Andrew Lindsley, Josh Courter, Amal Assa’ad
| Artículo siguiente Artículo siguiente
  • The Editors’ Choice
  • Zuhair K. Ballas, Associate Editors of the JACI

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.